- Home
- XENE vs FOLD Comparison
XENE vs FOLD Comparison
Compare XENE & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- FOLD
- Stock Information
- Founded
- XENE 1996
- FOLD 2002
- Country
- XENE Canada
- FOLD United States
- Employees
- XENE N/A
- FOLD N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- FOLD Health Care
- Exchange
- XENE Nasdaq
- FOLD Nasdaq
- Market Cap
- XENE 2.9B
- FOLD 2.5B
- IPO Year
- XENE 2014
- FOLD 2007
- Fundamental
- Price
- XENE $39.04
- FOLD $9.24
- Analyst Decision
- XENE Strong Buy
- FOLD Strong Buy
- Analyst Count
- XENE 10
- FOLD 8
- Target Price
- XENE $52.90
- FOLD $27.88
- AVG Volume (30 Days)
- XENE 795.3K
- FOLD 4.7M
- Earning Date
- XENE 11-03-2025
- FOLD 11-04-2025
- Dividend Yield
- XENE N/A
- FOLD N/A
- EPS Growth
- XENE N/A
- FOLD N/A
- EPS
- XENE N/A
- FOLD N/A
- Revenue
- XENE $7,500,000.00
- FOLD $571,160,000.00
- Revenue This Year
- XENE N/A
- FOLD $21.12
- Revenue Next Year
- XENE $207.88
- FOLD $21.23
- P/E Ratio
- XENE N/A
- FOLD N/A
- Revenue Growth
- XENE N/A
- FOLD 25.35
- 52 Week Low
- XENE $26.74
- FOLD $5.51
- 52 Week High
- XENE $46.00
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- XENE 41.74
- FOLD 67.95
- Support Level
- XENE $37.63
- FOLD $8.62
- Resistance Level
- XENE $42.96
- FOLD $9.64
- Average True Range (ATR)
- XENE 1.60
- FOLD 0.37
- MACD
- XENE -0.47
- FOLD 0.04
- Stochastic Oscillator
- XENE 21.42
- FOLD 77.12
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.